MedTrace Logo

Evaluating the Validity of a Genetic Risk Assessment Tool in Identifying Autism Spectrum Disorder

NCT01452061 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 456

Last updated 2014-01-29

No results posted yet for this study

Summary

There are three purposes to this study. The first purpose is to evaluate the value of a genetic test in determining risk for autism spectrum disorder. Processing for genetic samples will be completed at the Cleveland Clinic using research equipment provided by IntegraGen. The second purpose is to identify genetic changes that may be associated with autism spectrum disorder or attention deficit/hyperactivity disorder. The third purpose is to examine whether genetic differences and changes may predict which individuals benefit from medicine used to treat attention problems or other psychiatric difficulties.

Between 600-800 people are expected to participate in this study - approximately 300 individuals with an autism spectrum disorder, 75 individuals with attention deficit/hyperactivity disorder or another developmental or psychiatric disorder, 100 healthy siblings, and 125 unrelated individuals without a developmental or psychiatric disorder.

Study procedures will vary based upon the specific group participants are suspected to fall into (autism, attention deficit/hyperactivity disorder, psychiatric concerns/developmental delay, healthy sibling, or unrelated healthy control).

* All individuals will be asked to participate in a cheek swab (gently swabbing the inside of your cheek) to obtain cells used for genetic testing. Genetic material will be stored with identifiers such as numbers, letters or codes.
* Parents or caregivers will be asked to complete questionnaires that examine medical and family history as well as current symptoms and quality of life for the participant.
* Participants may undergo speech and language testing. This involves answering questions, looking at pictures or identifying items.
* Information recorded in participant medical records will be reviewed and collected for this study.

Conditions

Sponsors & Collaborators

  • IntegraGen SA

    collaborator INDUSTRY

  • Thomas W. Frazier, Ph.D

    lead OTHER

Principal Investigators

  • Thomas W Frazier, Ph.D. · The Cleveland Clinic

  • Charis Eng, M.D., Ph.D. · The Cleveland Clinic

Eligibility

Min Age
1 Year
Max Age
12 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2012-01-31
Primary Completion
2013-12-31
Completion
2013-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01452061 on ClinicalTrials.gov